Posts tagged Rodman & Renshaw
Cellect completes NASDAQ IPO

Cellect Biotechnology (NASDAQ:APOP; TASE:CLBD) priced an initial public offering in the U.S. of 1,292,308 American Depository Shares (ADSs) and warrants to purchase up to 969,231 ADSs.

Read More
Rodman starts Catalyst Biosciences at buy

odman & Renshaw initiated coverage of Catalyst Biosciences (NASDAQ:CLIO) with a “buy” rating and a 12-month price target of $3.50. The stock closed at $1.25 on Wednesday.

Using its proprietary protease platform, Catalyst Biosciences is advancing its lead hemostasis programs for hemophilia A and B, as well as its anti- complement programs, which could be applicable across various other disorders, including delayed graft function in kidney transplantation and age-related macular degeneration, a chronic eye disease.

Read More
Rodman starts Presbia at buy

Rodman & Renshaw has initiated coverage of Presbia PLC (NASDAQ:LENS) with the “buy” rating and 18-month price target of $14. The stock closed at $3.90 on Tuesday.

Presbia has a novel corneal inlay product, the Flexivue Microlens, aimed at treating presbyopia, or nearsightedness.

Read More
Rodman starts LabStyle Innovations at buy

Rodman & Renshaw has initiated coverage of LabStyle Innovations (NASDAQ:DRIO) with a “buy” rating and $12 price target. The stock closed at $5.40 on Friday.

LabStyle is an emerging digital health company focused on the monitoring and management of diabetes.

Read More
TearLab prices $17.3-million registered public offering

TearLab (NASDAQ:TEAR; TSX:TLB) has priced a public offering of common stock to raised gross proceeds of approximately $17.3-million to close on May 9.

The offering was priced at 75 cents a share of common stock, or common stock equivalent, with each share of common stock coupled with a warrant to purchase one-half of one share of common stock.

Read More
Rodman starts Bio-Path at buy

Rodman & Renshaw has launched coverage of Bio-Path Holdings (NASDAQ:BPTH) with a “buy” rating and a 12-month price target of $5. The stock closed at $2.76 on Monday.

“In our view, Bio-Path’s unique liposomal delivery of antisense DNA has the potential to significantly improve treatment outcomes in elderly patients (≥60 years) with acute myeloid leukemia (AML),” writes analyst Raghuram Selvaraju.

Read More
Rodman assumes coverage of Semler Scientific at buy

Rodman & Renshaw analyst Raghuram Selvaraju has assumed coverage of Semler Scientific (NASDAQ:SMLR) with a “buy” rating and $8 price target. The stock was quoted at $2.05 Friday afternoon.

Semler’s 2015 revenue of $7-million represented growth of 93% over the 2014 revenue of $3.6-million. “In our view, the solid revenue growth demonstrates the continual market penetration of the company’s FloChec system, which is used to measure arterial blood flow in the extremities for risk assessment of peripheral arterial disease,” Mr. Selvaraju writes.

Read More
Rodman assumes coverage of NephroGenex at neutral

Rodman & Renshaw analyst Raghuram Selvaraju has assumed coverage of NephroGenex (NASDAQ:NRX) with a “neutral” rating and without a price target. The stock was quoted at 40 cents Friday afternoon.

The board of NephroGenex decided in late February 2016 to pause the oral Pyridorin pivotal program in diabetic nephropathy, to effect a restructuring of the company’s operations and implement a strategic transaction.

Read More
Shaunak Deepak joins H.C. Wainwright

Shaunak Deepak has joined H.C. Wainwright as a managing director and senior biotechnology analyst in the firm’s equity research group.

Mr. Deepak previously was a VP and biotech analyst with Jefferies since 2009. He also has been an associate in the life sciences equity research departments of Piper Jaffray, Rodman & Renshaw and Stifel, Nicolaus.

Read More
Rodman starts Nanosphere at buy

Rodman & Renshaw has launched coverage of Nanosphere (NASDAQ:NSPH) with a “buy” rating and price target of $2. The stock closed at 87 cents on Monday.

“In our view, the company’s Verigene system and test panels are differentiated from competing systems in that it is based on the gold nanoparticle technology for direct detection of pathogens without the use of PCR, and it offers test and pricing flexibility while having multiplex capacity (identifying multiple targets in one test),” writes analyst Yi Chen.

Read More
Rodman starts BioSpecifics at buy

Rodman & Renshaw has started coverage of BioSpecifics Technologies (NASDAQ:BSTC) with a “buy” rating and 12-month price target of $60. The stock closed at $35.97 on Monday.

The company’s sole product is the collagenase clostridium histolyticum (CCH) for injection, which is approved for the treatment of Dupuytren’s contracture and Peyronie’s disease both in the U.S. and Europe. CCH also recently received regulatory approval in Japan for Dupuytren’s contracture and in Switzerland for Peyronie’s disease.

Read More
Rodman starts EyeGate Pharma at buy

Rodman & Renshaw has launched coverage of EyeGate Pharmaceuticals (NASDAQ:EYEG) with a “buy’ rating and a 12-month price target of $10. The stock closed at $1.70 on Friday.

"In our view, the company’s EGP-437 combination product is differentiated from eye drops and intraocular injections in that it is non-invasive and solves patient non-compliance and safety issues that currently plague conventional ophthalmic drug delivery methods,” writes analyst Yi Chen.

Read More
Rodman starts VolitionRx at buy

Rodman & Renshaw has initiated coverage of VolitionRx (NASDAQ:VNRX) with a “buy” rating and a 12-month price target of $12. The stock closed at $3.77 on Friday.

“In our view, the company’s blood-based NuQ screening test for colorectal cancer, based on its proprietary nucleosomics epigenetic biomarker platform, is differentiated from traditional detection methods and other competing blood-based technologies in terms of accuracy, convenience and pricing,” writes analyst Yi Chen.

Read More
Rodman starts BioBlast Pharma at buy

Rodman & Renshaw has initiated coverage of BioBlast Pharma (NASDAQ:ORPN) with a “buy” rating and 12-month price target of $25. The stock closed at $3.24 on Wednesday.

BioBlast is focused on platform-based solutions, addressing rare diseases due to mitochondrial dysfunction and misfolding of critical function proteins.

Read More
Rodman starts InspireMD at buy

Rodman & Renshaw has initiated coverage of InspireMD (NYSE MKT:NSPR) with a “buy” rating and 12-month price target of $4. The stock closed at 71 cents on Thursday.

InspireMD is a commercial-stage company focusing on the development and marketing of stents covered with proprietary knitted mesh for coronary and carotid artery diseases.

Read More